Medacta Group SA (CH:MOVE)
:MOVE
Want to see CH:MOVE full AI Analyst Report?
Top Page
Medacta Group SA
(MOVE)
Select Model
Select Model
Rating:64Neutral
Price Target:
CHF164.00
▼(-2.38% Downside)
Action:ReiteratedDate:04/13/26
The score is driven primarily by strong financial performance (growth and healthy margins), tempered by volatile/uneven free cash flow. Technicals are neutral to slightly soft (negative MACD and trading below key medium-term averages), and valuation is a headwind due to a high P/E and low dividend yield.
Positive Factors
Sustained revenue growth & strong margins
Multi-year revenue growth to €688M and durable high gross and EBITDA margins indicate a strong product franchise in orthopedic implants. That combination supports recurring procedure-linked sales, funds R&D and commercial investment, and provides structural resilience to demand cycles over months.
Negative Factors
Uneven free cash flow conversion
Volatile FCF conversion—negative in 2023, minimal in 2024, modest in 2025—signals working-capital swings or lumpy capex. Persistently uneven cash conversion can limit predictable funding for growth or shareholder returns and increases sensitivity to operational disruptions.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth & strong margins
Multi-year revenue growth to €688M and durable high gross and EBITDA margins indicate a strong product franchise in orthopedic implants. That combination supports recurring procedure-linked sales, funds R&D and commercial investment, and provides structural resilience to demand cycles over months.
Read all positive factors
Medacta Group SA (MOVE) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF2.83B
Dividend Yield0.45%
Average Volume (3M)12.13K
Price to Earnings (P/E)34.9
Beta (1Y)0.81
Revenue Growth13.93%
EPS Growth28.92%
CountryCH
Employees1,907
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.66
Shares Outstanding20,000,000
10 Day Avg. Volume8,750
30 Day Avg. Volume12,134
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)7.36
Price to Sales (P/S)4.88
P/FCF Ratio112.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF168.00Price Target Upside0.00%
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)5.17
Revenue Forecast (FY)CHF767.46M
Medacta Group SA Business Overview & Revenue Model
Company Description
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. It offers personalized kinematic models and 3D planning tools for use in hip, knee,...
How the Company Makes Money
Medacta primarily makes money by selling orthopedic medical devices to healthcare providers (e.g., hospitals and surgical centers) and through distribution channels that supply surgeons and institutions. Its core revenue streams are product sales ...
Medacta Group SA Earnings Call Summary
Earnings Call Date:Sep 08, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Sep 04, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong revenue and net profit growth, with significant achievements across product lines and a successful acquisition. However, challenges remain in maintaining growth and managing costs and margins going into the second half of the year.Positive Updates
Strong Revenue Growth
First half 2025 revenues reached EUR 344.1 million, marking an increase of 19.8% in constant currency.
Negative Updates
Slight Decline in Gross Margin
Gross profit margin slightly declined from 68.5% to 68.3%, mainly due to FX effects.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong Revenue Growth
First half 2025 revenues reached EUR 344.1 million, marking an increase of 19.8% in constant currency.
Read all positive updates
Company Guidance
During the Medacta First Half 2025 Results Conference Call, CEO Francesco Siccardi and CFO Corrado Farsetta provided detailed guidance, highlighting a strong H1 revenue of EUR 344.1 million, marking a 19.8% increase in constant currency. The adjusted EBITDA margin was reported at 29.6%, an improvement from the previous year's 26.9%, with net profit reaching EUR 60 million, up 58% from H1 2024. Medacta confirmed a full-year revenue growth target of 16% to 18% in constant currency, with an adjusted EBITDA margin of about 28%. The company's strategic focus on innovation, personalized medical education, and geographic expansion, including potential U.S. manufacturing, were emphasized as key growth drivers. Additionally, Medacta's acquisition of Parcus was noted for its positive impact, including a net one-off gain of EUR 12 million. The company plans to maintain its above-market growth trajectory, aiming for a midterm revenue CAGR of 10% to 14% through 2027.Medacta Group SA Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
76
Positive
Cash Flow
63
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 688.27M | 590.58M | 510.78M | 437.12M | 363.13M |
| Gross Profit | 441.40M | 399.44M | 347.85M | 305.26M | 261.25M |
| EBITDA | 190.55M | 160.51M | 119.64M | 106.96M | 97.81M |
| Net Income | 96.12M | 72.89M | 47.36M | 46.25M | 51.52M |
Balance Sheet | |||||
| Total Assets | 916.93M | 792.18M | 695.87M | 584.49M | 489.27M |
| Cash, Cash Equivalents and Short-Term Investments | 33.19M | 31.59M | 20.79M | 32.26M | 20.40M |
| Total Debt | 262.56M | 241.21M | 201.98M | 170.25M | 132.66M |
| Total Liabilities | 460.71M | 412.51M | 365.83M | 309.83M | 262.87M |
| Stockholders Equity | 456.22M | 379.66M | 330.04M | 274.65M | 226.40M |
Cash Flow | |||||
| Free Cash Flow | 29.90M | 2.45M | -7.09M | 10.35M | 7.57M |
| Operating Cash Flow | 153.65M | 107.14M | 75.13M | 73.51M | 54.06M |
| Investing Cash Flow | -137.86M | -98.87M | -80.61M | -65.11M | -52.04M |
| Financing Cash Flow | -18.91M | 4.33M | -10.13M | 3.44M | -31.21M |
Medacta Group SA Technical Analysis
Positive
168.00
Price Trends
153.75
Positive
156.55
Positive
151.42
Positive
Market Momentum
1.14
Negative
62.56
Neutral
80.34
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MOVE, the sentiment is Positive. The current price of 168 is above the 20-day moving average (MA) of 152.53, above the 50-day MA of 153.75, and above the 200-day MA of 151.42, indicating a bullish trend. The MACD of 1.14 indicates Negative momentum. The RSI at 62.56 is Neutral, neither overbought nor oversold. The STOCH value of 80.34 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:MOVE.
Medacta Group SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | CHF3.72B | 7.66 | 27.15% | 0.67% | 27.63% | 160.67% | |
66 Neutral | CHF13.47B | 41.72 | ― | 1.02% | 4.05% | -7.94% | |
64 Neutral | CHF2.83B | 34.95 | 23.76% | 0.45% | 13.93% | 28.92% | |
61 Neutral | CHF1.51B | -3.17 | 4.57% | 2.31% | -5.54% | -264.90% | |
56 Neutral | CHF796.05M | 498.59 | -7.82% | ― | 59.85% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | CHF1.05B | 131.13 | ― | ― | 19.76% | 150.73% |
* General Sector Average
CH:MOVE
Medacta Group SA
141.60
3.68
2.67%
CH:STMN
Straumann Holding AG
84.50
-18.01
-17.57%
CH:KURN
Kuros Biosciences
20.28
-7.02
-25.71%
CH:TECN
Tecan Group AG
117.70
-40.73
-25.71%
CH:YPSN
Ypsomed Holding AG
273.00
-82.62
-23.23%
CH:MED
Medartis Holding AG
76.90
2.10
2.81%
Medacta Group SA Corporate Events
Medacta Calls 2026 AGM With Dividend and Board Re-Elections on Agenda
Apr 7, 2026
Medacta Group SA has issued the invitation to its 2026 Annual General Meeting, scheduled for 5 May 2026 at its premises in Rancate, Switzerland, where shareholders may attend in person or vote via independent or third-party proxies. The Board will...
Medacta Uses Dinosaur “Hip Implant” Project as April Fools’ Showcase of Innovation
Apr 1, 2026
Medacta Group SA briefly announced its fictional selection as a partner in an international project to recreate dinosaurs from preserved DNA, highlighting a tongue-in-cheek plan to develop an oversized orthopaedic hip prosthesis for a Tyrannosauru...
Medacta Delivers Record 2025 Results and Lifts Growth Targets on Broad-Based Orthopaedics Momentum
Mar 13, 2026
Medacta Group SA, a Swiss orthopaedics manufacturer listed on SIX under the ticker MOVE, develops implants and surgical technologies for hip, knee, spine and extremities procedures, with a strong emphasis on minimally invasive techniques and perso...
Medacta Delivers 18.5% Constant-Currency Revenue Growth in 2025 on Broad-Based Demand
Feb 3, 2026
Medacta Group SA reported another year of robust, above-market expansion in 2025, with preliminary unaudited revenue rising 18.5% in constant currency (15.8% in euro) to €683.8 million, driven by double-digit growth in all major regions and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.